Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

794.38 +2.08 (+0.26%)
Streaming Delayed Price Updated: 3:06 PM EDT, Jun 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
New AI Rollouts Signal Shift From Hype to Healthcare Reality
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:LLY),(NASDAQ:PLTR),(NYSE:PHG),(NASDAQ:WAY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
May 2025 Industrial Manufacturing Near March 2025 Levels with 146 New Planned Capital Projects Heading into Summer
JACKSONVILLE, Fla., June 17, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads announced today the May 2025 results for its new planned capital project spending report for the Industrial... 
Via Send2Press
Bila Solar’s Indiana Factory Commences Production of Domestic Solar Panels, Strengthening U.S. Clean Energy Manufacturing at Key Policy Moment
Behind-the-scenes video captures this milestone for American solar — creating local jobs and reinforcing why federal support for clean energy matters 
Via News Direct
Topics Economy
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Via PR Leap
Ireland: America’s Gateway to Europe – The $2 Trillion Investment Story
Via AB Newswire
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
Organovo Provides Business Update
From Organovo, Inc.
Via GlobeNewswire
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
From Organovo, Inc.
Via GlobeNewswire
Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum
Via AB Newswire
Topics Artificial Intelligence Derivatives Intellectual Property
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
From Organovo, Inc.
Via GlobeNewswire
In 2025, the pharmaceutical industry is ripe for M&A
Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment for mergers and acquisitions 
Via Equities.com
Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of Directors
Austin, Texas--(Newsfile Corp. - January 22, 2025) - Maxwell Biosciences ("Maxwell"), a pre-clinical drug platform company that develops Claromers™, ... 
Via Newsfile
Soricimed Biopharma Appoints Dr. Neil Fleshner as Executive Board Member
Moncton, New Brunswick, Canada--(Newsfile Corp. - January 13, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on... 
Via Newsfile
LeapFrog Investments raises more than $1 billion for impact health investing
LeapFrog Investments said this week it has raised more than $1 billion in a new investment fund that targets high-impact health and financial-services 
Via Equities.com
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
From Verge Genomics
Via GlobeNewswire
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
Via MarketBeat
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. 
Via MarketBeat
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree 
Via MarketBeat
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. 
Via MarketBeat
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth. 
Via MarketBeat
Topics Stocks
3 Momentum Trades Too Good Pass Up
Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going. 
Via MarketBeat
Topics ETFs
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr.... 
Via Newsfile
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.